Please use this identifier to cite or link to this item:
http://repository.kln.ac.lk/handle/123456789/1389
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Premawardhena, A.P. | en_US |
dc.contributor.author | de Silva, C.E. | en_US |
dc.contributor.author | Fonseka, M.M.D. | en_US |
dc.contributor.author | Gunatilake, S.B. | en_US |
dc.contributor.author | de Silva, H.J. | en_US |
dc.date.accessioned | 2014-10-29T09:18:16Z | |
dc.date.available | 2014-10-29T09:18:16Z | |
dc.date.issued | 1999 | en_US |
dc.identifier.citation | British Medical Journal. 1999; 318(7190): 1041-43 | en_US |
dc.identifier.issn | 0959-8138 (Print) | en_US |
dc.identifier.issn | 1756-1833 (Electronic) | en_US |
dc.identifier.uri | http://repository.kln.ac.lk/handle/123456789/1389 | |
dc.description | Indexed in MEDLINE | |
dc.description.abstract | OBJECTIVE: To assess the efficacy and safety of low dose adrenaline injected subcutaneously to prevent acute adverse reactions to polyspecific antivenom serum in patients admitted to hospital after snake bite. DESIGN: Prospective, double blind, randomised, placebo controlled trial. SETTING: District general hospital in Sri Lanka. SUBJECTS: 105 patients with signs of envenomation after snake bite, randomised to receive either adrenaline (cases) or placebo (controls) immediately before infusion of antivenom serum. INTERVENTIONS: Adrenaline 0.25 ml (1:1000). MAIN OUTCOME MEASURES: Development of acute adverse reactions to serum and side effects attributable to adrenaline. RESULTS: 56 patients (cases) received adrenaline and 49 (controls) received placebo as pretreatment. Six (11percent) adrenaline patients and 21 (43 percent) control patients developed acute adverse reactions to antivenom serum (P=0.0002). Significant reductions in acute adverse reactions to serum were also seen in the adrenaline patients for each category of mild, moderate, and severe reactions. There were no significant adverse effects attributable to adrenaline. CONCLUSIONS: Use of 0.25 ml of 1:1000 adrenaline given subcutaneously immediately before administration of antivenom serum to patients with envenomation after snake bite reduces the incidence of acute adverse reactions to serum. | en_US |
dc.publisher | British Medical Association | en_US |
dc.subject | Snake Bites | en_US |
dc.subject | Randomized Controlled Trial | en_US |
dc.subject | Snake Bites-drug therapy | en_US |
dc.subject | Epinephrine-administration and dosage | en_US |
dc.subject | Antivenins-adverse effects | en_US |
dc.title | Low dose subcutaneous adrenaline to prevent acute adverse reactions to antivenom serum in people bitten by snakes: randomised, placebo controlled trial | en_US |
dc.type | Article | en_US |
dc.identifier.department | Medicine | en_US |
dc.creator.corporateauthor | British Medical Association | en_US |
Appears in Collections: | Journal/Magazine Articles |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.